Cargando…

Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2

The acquisition of temozolomide resistance is a major clinical challenge for glioblastoma treatment. Chemoresistance in glioblastoma is largely attributed to repair of temozolomide-induced DNA lesions by O(6)-methylguanine-DNA methyltransferase (MGMT). However, some MGMT-deficient glioblastomas are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yi, Guo-zhong, Huang, Guanglong, Guo, Manlan, Zhang, Xi’an, Wang, Hai, Deng, Shengze, Li, Yaomin, Xiang, Wei, Chen, Ziyang, Pan, Jun, Li, Zhiyong, Yu, Lei, Lei, Bingxi, Liu, Yawei, Qi, Songtao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658867/ https://www.ncbi.nlm.nih.gov/pubmed/31347685 http://dx.doi.org/10.1093/brain/awz202

Ejemplares similares

Expression of dynein, cytoplasmic 2, heavy chain 1 (DHC2) associated with glioblastoma cell resistance to temozolomide
por: Wang, Hai, et al.
Publicado: (2016)

Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
por: Thomas, Reena P, et al.
Publicado: (2012)

Albumin-bound paclitaxel augment temozolomide treatment sensitivity of glioblastoma cells by disrupting DNA damage repair and promoting ferroptosis
por: Qu, Shanqiang, et al.
Publicado: (2023)

Correction: albumin-bound paclitaxel augment temozolomide treatment sensitivity of glioblastoma cells by disrupting DNA damage repair and promoting ferroptosis
por: Qu, Shanqiang, et al.
Publicado: (2023)

Acquired temozolomide resistance in MGMT(low) gliomas is associated with regulation of homologous recombination repair by ROCK2
por: Zhang, Xin, et al.
Publicado: (2022)

Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival
por: Rahman, Mohummad Aminur, et al.
Publicado: (2019)

PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O(6)-methylguanine DNA damage in glioblastoma
por: Wu, Shaofang, et al.
Publicado: (2021)

EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma
por: Struve, Nina, et al.
Publicado: (2020)

Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma
por: Ganesa, Sachita, et al.
Publicado: (2022)

Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy
por: Dunn, J, et al.
Publicado: (2009)

A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
por: Chen, Xiaoyue, et al.
Publicado: (2018)

The Impact of MGMT Promoter Methylation and Temozolomide Treatment in Serbian Patients with Primary Glioblastoma
por: Jovanović, Nikola, et al.
Publicado: (2019)

The DHC1b (DHC2) Isoform of Cytoplasmic Dynein Is Required for Flagellar Assembly
por: Pazour, Gregory J., et al.
Publicado: (1999)

Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma
por: Faye, Mame Daro, et al.
Publicado: (2023)

Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital
por: Egaña, Larraitz, et al.
Publicado: (2020)

On the Critical Issues in Temozolomide Research in Glioblastoma: Clinically Relevant Concentrations and MGMT-independent Resistance
por: Stepanenko, Aleksei A., et al.
Publicado: (2019)

Lack of Benefit of Extending Temozolomide Treatment in Patients with High Vascular Glioblastoma with Methylated MGMT
por: Álvarez-Torres, María del Mar, et al.
Publicado: (2021)

BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
por: Tancredi, Alessandro, et al.
Publicado: (2022)

Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastoma
por: Han, Xinyu, et al.
Publicado: (2023)

Identification of MGMT Downregulation Induced by miRNA in Glioblastoma and Possible Effect on Temozolomide Sensitivity
por: Cardia, Andrea, et al.
Publicado: (2023)

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide
por: van Nifterik, K A, et al.
Publicado: (2010)

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
por: Melguizo, Consolación, et al.
Publicado: (2012)

Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma
por: Wang, Ke, et al.
Publicado: (2017)

Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status
por: Wu, Qiong, et al.
Publicado: (2023)

Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit
por: Castro, Michael, et al.
Publicado: (2021)

Nucleo-cytoplasmic shuttling of 14-3-3 epsilon carrying hnRNP C promotes autophagy
por: Guo, Manlan, et al.
Publicado: (2023)

Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression
por: Perazzoli, Gloria, et al.
Publicado: (2015)

A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide
por: Chai, Rui-Chao, et al.
Publicado: (2019)

Overexpression miR-486-3p Promoted by Allicin Enhances Temozolomide Sensitivity in Glioblastoma Via Targeting MGMT
por: Wu, Henggang, et al.
Publicado: (2020)

Crosstalk between glioblastoma and tumor microenvironment drives proneural–mesenchymal transition through ligand-receptor interactions
por: Lai, Yancheng, et al.
Publicado: (2023)

Resveratrol Enhances Temozolomide Efficacy in Glioblastoma Cells through Downregulated MGMT and Negative Regulators-Related STAT3 Inactivation
por: Wu, Moli, et al.
Publicado: (2023)

DGKI Methylation Status Modulates the Prognostic Value of MGMT in Glioblastoma Patients Treated with Combined Radio-Chemotherapy with Temozolomide
por: Etcheverry, Amandine, et al.
Publicado: (2014)

Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma
por: Nie, Er, et al.
Publicado: (2018)

Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis
por: Alnahhas, Iyad, et al.
Publicado: (2020)

TGF-β1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT
por: Nie, Er, et al.
Publicado: (2020)

A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study
por: Sim, Hao-Wen, et al.
Publicado: (2021)

Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies
por: Kurdi, Maher, et al.
Publicado: (2021)

Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
por: Lim, Michael, et al.
Publicado: (2022)

Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells
por: Qiu, Zhi-Kun, et al.
Publicado: (2014)

Pyrvinium pamoate regulates MGMT expression through suppressing the Wnt/β-catenin signaling pathway to enhance the glioblastoma sensitivity to temozolomide
por: Li, Haisong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cq6ef5q0ua601g0nrlj8hp0gv3